<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>1817-5996</journal-id>
<journal-title><![CDATA[Revista Cubana de Reumatología]]></journal-title>
<abbrev-journal-title><![CDATA[Rev Cuba Reumatol]]></abbrev-journal-title>
<issn>1817-5996</issn>
<publisher>
<publisher-name><![CDATA[Editorial CIMEQ]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S1817-59962023000400002</article-id>
<title-group>
<article-title xml:lang="es"><![CDATA[Comportamiento de la actividad clínica y la respuesta al tratamiento en pacientes con artritis reumatoide tratados con Jusvinza]]></article-title>
<article-title xml:lang="en"><![CDATA[Behavior of the clinical activity and treatment response in patients with rheumatoid arthritis treated with Jusvinza]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Prada Hernández]]></surname>
<given-names><![CDATA[Dinorah Marisabel]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Gómez Morejón]]></surname>
<given-names><![CDATA[Jorge Alexis]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Molinero Rodríguez]]></surname>
<given-names><![CDATA[Claudino]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Domínguez-Horta]]></surname>
<given-names><![CDATA[María del Carmen]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Pozo Abreu]]></surname>
<given-names><![CDATA[Silvia María]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Reyes Pineda]]></surname>
<given-names><![CDATA[Yusimí]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Ordaz Acosta]]></surname>
<given-names><![CDATA[Arisel]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Hortelas Sánchez]]></surname>
<given-names><![CDATA[Dianayis]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Ruiz Vaquero]]></surname>
<given-names><![CDATA[Rene]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
</contrib-group>
<aff id="Af1">
<institution><![CDATA[,Universidad de Ciencias Médicas de La Habana Centro de Referencia para las Enfermedades Reumáticas ]]></institution>
<addr-line><![CDATA[La Habana ]]></addr-line>
<country>Cuba</country>
</aff>
<aff id="Af2">
<institution><![CDATA[,Centro de Ingeniería Genética y Biotecnología. CIGB División farmacéutica ]]></institution>
<addr-line><![CDATA[La Habana ]]></addr-line>
<country>Cuba</country>
</aff>
<aff id="Af3">
<institution><![CDATA[,Universidad de Ciencias Médicas de La Habana Hospital Docente Clínico Quirúrgico 10 de Octubre ]]></institution>
<addr-line><![CDATA[La Habana ]]></addr-line>
<country>Cuba</country>
</aff>
<aff id="Af4">
<institution><![CDATA[,Universidad de Ciencias Médicas de La Habana Hospital Docente Clínico Quirúrgico ``Joaquín Albarrán ]]></institution>
<addr-line><![CDATA[La Habana ]]></addr-line>
<country>Cuba</country>
</aff>
<aff id="Af5">
<institution><![CDATA[,Universidad de Ciencias Médicas de La Habana Facultad de Ciencias Médicas 10 de Octubre ]]></institution>
<addr-line><![CDATA[La Habana ]]></addr-line>
<country>Cuba</country>
</aff>
<pub-date pub-type="pub">
<day>00</day>
<month>12</month>
<year>2023</year>
</pub-date>
<pub-date pub-type="epub">
<day>00</day>
<month>12</month>
<year>2023</year>
</pub-date>
<volume>25</volume>
<numero>4</numero>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://scielo.sld.cu/scielo.php?script=sci_arttext&amp;pid=S1817-59962023000400002&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://scielo.sld.cu/scielo.php?script=sci_abstract&amp;pid=S1817-59962023000400002&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://scielo.sld.cu/scielo.php?script=sci_pdf&amp;pid=S1817-59962023000400002&amp;lng=en&amp;nrm=iso"></self-uri><abstract abstract-type="short" xml:lang="es"><p><![CDATA[RESUMEN  Introducción: La inducción de inmunotolerancia como abordaje terapéutico en la artritis reumatoide constituye un foco de investigación actual. Los resultados del ensayo clínico fase I Seguridad y farmacocinética del CIGB 814 en pacientes con artritis reumatoide, indicaron evidencias preliminares de eficacia clínica.  Objetivo: Describir las características clínicas de los pacientes tratados con el candidato terapéutico CIGB 814, Jusvinza después de haber concluido el ensayo clínico.  Método: Se realizó un estudio descriptivo y observacional de los pacientes con artritis reumatoide tratados con el CIGB 814, a los 12 y 24 meses después de concluido el ensayo clínico, durante el período comprendido de septiembre del 2016 a julio del 2018, en el Centro de Referencia de Enfermedades Reumáticas del Hospital Docente Clínico Quirúrgico. 10 de Octubre. La muestra quedó constituida por 17 pacientes, la información de las variables cuantitativas se resumió mediante su número absoluto y por ciento. Para el análisis e interpretación de los resultados se utilizó el análisis porcentual.  Resultados: La media del DAS 28 se correspondió con pacientes en remisión y discapacidad funcional leve. Desde la semana 48, final del ensayo clínico hasta los 24 meses el 64,7 % se mantiene en remisión sostenida. En la evaluación final el 82,30 % expresan 70 % de mejoría (ACR 70) y el 88,2 % con buena respuesta EULAR. El 70, 60% se encuentran sin discapacidad funcional. (HAQ CU =0)  Conclusiones: A los 12 y 24 meses los pacientes mantienen la mejoría clínica alcanzada durante el periodo del ensayo clínico, con un incremento de la mejoría de la capacidad funcional. Se observó la reducción de las necesidades del consumo de antinflamatorios no esteroideos, esteroides y metotrexate para el control de la enfermedad.]]></p></abstract>
<abstract abstract-type="short" xml:lang="en"><p><![CDATA[ABSTRACT  Introduction: Currently, the induction of immune tolerance as a therapeutic approach in rheumatoid arthritis is an interesting focus of research. The results of the Phase I Clinical Trial Safety and pharmacokinetics of CIGB-814 in patients with rheumatoid arthritis, indicated preliminary evidence of clinical efficacy.  Objective: To describe the clinical characteristics of patients treated with the therapeutic candidate CIGB-814, Jusvinza after the conclusion of the clinical trial  Method: A descriptive, observational study of patients with rheumatoid arthritis treated with the CIGB 814 was carried out, at 12 and 24 months after the end of the clinical trial, during the period from September 2016 to June 2018, at the Reference Center for Rheumatic Diseases (Surgical Clinical Teaching Hospital October 10th). This study included 17 patients. The information of the quantitative variables was summarized by their absolute number and percentage. For the analysis and interpretation of the results, the percentage analysis was used.  Result: The clinical evaluation by DAS 28 indicated that the patients fell into remission and they had functional disability mild. 64.7% of the patients remain in sustained remission after 12 months of concluded the clinical trial. In the final evaluation, 82.30 % expressed 70 % improvement (ACR 70) and 88.2 % with a good EULAR response. 70.60 % of patients are without functional disability. (HAQCU=0)  Conclusion: At 12 and 24 months, patients maintained the clinical improvement achieved during the period of clinical trial, with an increase of improvement in the functional capacity. In addition, a reduction in the consumption of NSAIDs, steroids and methotrexate for the control of the disease was observed in all patients.]]></p></abstract>
<kwd-group>
<kwd lng="es"><![CDATA[artritis reumatoide]]></kwd>
<kwd lng="es"><![CDATA[terapia inmunomoduladora]]></kwd>
<kwd lng="es"><![CDATA[Jusvinza]]></kwd>
<kwd lng="es"><![CDATA[CIGB -814]]></kwd>
<kwd lng="en"><![CDATA[rheumatoid arthritis]]></kwd>
<kwd lng="en"><![CDATA[immunomodulatory therapy]]></kwd>
<kwd lng="en"><![CDATA[Jusvinza]]></kwd>
<kwd lng="en"><![CDATA[CIGB -814]]></kwd>
</kwd-group>
</article-meta>
</front><back>
<ref-list>
<ref id="B1">
<label>1</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Sánchez-Piedra]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Miguel]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Manero]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Roselló]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Sánchez-Costa]]></surname>
<given-names><![CDATA[JT]]></given-names>
</name>
<name>
<surname><![CDATA[Rodríguez-Lozano]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Objetivos y metodología de la fase III de BIOBADASER]]></article-title>
<source><![CDATA[Reumatol Clin]]></source>
<year>2019</year>
<volume>15</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>229-36</page-range></nlm-citation>
</ref>
<ref id="B2">
<label>2</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Landoño]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Peláes Ballesta]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
<name>
<surname><![CDATA[Cuervo]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Angarita]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
<name>
<surname><![CDATA[Giraldo]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Rueda]]></surname>
<given-names><![CDATA[JC]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Prevalencia de la enfermedad reumática en Colombia, según estrategia COPCORD- Asociación Colombiana de Reumatología. Estudio de prevalencia de enfermedad reumática en población colombiana mayor de 18 años]]></article-title>
<source><![CDATA[Rev Colomb Reumatol]]></source>
<year>2018</year>
<volume>25</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>245-56</page-range></nlm-citation>
</ref>
<ref id="B3">
<label>3</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Schneeberger]]></surname>
<given-names><![CDATA[EE]]></given-names>
</name>
<name>
<surname><![CDATA[Acosta Felquer]]></surname>
<given-names><![CDATA[MA]]></given-names>
</name>
<name>
<surname><![CDATA[Citera]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Soriano]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Mysler]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Persistencia a largo plazo de agentes biológicos en el tratamiento de pacientes con Artritis Reumatoidea: una revisión sistemática de la literatura]]></article-title>
<source><![CDATA[Rev. argent. reumatolg]]></source>
<year>2020</year>
<volume>31</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>6-18</page-range></nlm-citation>
</ref>
<ref id="B4">
<label>4</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Smolen]]></surname>
<given-names><![CDATA[JS]]></given-names>
</name>
<name>
<surname><![CDATA[Landewé]]></surname>
<given-names><![CDATA[RBM]]></given-names>
</name>
<name>
<surname><![CDATA[Bijlsma]]></surname>
<given-names><![CDATA[JWJ]]></given-names>
</name>
<name>
<surname><![CDATA[Burmester]]></surname>
<given-names><![CDATA[GR]]></given-names>
</name>
<name>
<surname><![CDATA[Dougados]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Kerschbaumer]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update]]></article-title>
<source><![CDATA[Ann Rheum Dis]]></source>
<year>2020</year>
<volume>79</volume>
<numero>6</numero>
<issue>6</issue>
</nlm-citation>
</ref>
<ref id="B5">
<label>5</label><nlm-citation citation-type="">
<source><![CDATA[Unión Europea]]></source>
<year>2016</year>
</nlm-citation>
</ref>
<ref id="B6">
<label>6</label><nlm-citation citation-type="book">
<collab>FDA</collab>
<source><![CDATA[Research C for DE and. Drug Approvals and Databases]]></source>
<year>2021</year>
<publisher-name><![CDATA[FDA]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B7">
<label>7</label><nlm-citation citation-type="">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Acosta Ruge]]></surname>
<given-names><![CDATA[NC]]></given-names>
</name>
<name>
<surname><![CDATA[Arévalo Gutiérrez]]></surname>
<given-names><![CDATA[MA]]></given-names>
</name>
<name>
<surname><![CDATA[Castellanos Molina]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
<name>
<surname><![CDATA[Durán Torres]]></surname>
<given-names><![CDATA[PM]]></given-names>
</name>
</person-group>
<source><![CDATA[Costo efectividad de tofacitinib vs baricitinib en artritis reumatoide en Colombia]]></source>
<year>2021</year>
<publisher-loc><![CDATA[Bogotá, Colombia ]]></publisher-loc>
</nlm-citation>
</ref>
<ref id="B8">
<label>8</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Taylor]]></surname>
<given-names><![CDATA[PC]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Clinical efficacy of launched JAK inhibitors in rheumatoid arthritis]]></article-title>
<source><![CDATA[Rheumatology (Oxford)]]></source>
<year>2019</year>
<volume>58</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>17-26</page-range></nlm-citation>
</ref>
<ref id="B9">
<label>9</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Schlueter]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Finn]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Díaz]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Dilla]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Inciarte-Mundo]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Fakhouri]]></surname>
<given-names><![CDATA[W]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Cost-effectiveness analysis of baricitinib versus adalimumab for the treatment of moderate-tosevere rheumatoid arthritis in Spain]]></article-title>
<source><![CDATA[Clin Outcomes Res]]></source>
<year>2019</year>
<volume>11</volume>
<page-range>395-403</page-range></nlm-citation>
</ref>
<ref id="B10">
<label>10</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Navarro]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Martínez-Sesmero]]></surname>
<given-names><![CDATA[JM]]></given-names>
</name>
<name>
<surname><![CDATA[Balsa]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Peral]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Montoro]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Valderrama]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Costeffectiveness analysis of treatment sequences containing tofacitinib for the treatment of rheumatoid arthritis in Spain]]></article-title>
<source><![CDATA[Clin Rheumatol]]></source>
<year>2020</year>
<volume>39</volume>
<numero>10</numero>
<issue>10</issue>
<page-range>2919-30</page-range></nlm-citation>
</ref>
<ref id="B11">
<label>11</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Urbina Aucancela]]></surname>
<given-names><![CDATA[CY]]></given-names>
</name>
<name>
<surname><![CDATA[Carrera Montero]]></surname>
<given-names><![CDATA[GY]]></given-names>
</name>
<name>
<surname><![CDATA[Quintana Domínguez]]></surname>
<given-names><![CDATA[OS]]></given-names>
</name>
<name>
<surname><![CDATA[Guama Bonilla]]></surname>
<given-names><![CDATA[LN]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Actividad y tratamiento de la artritis reumatoide]]></article-title>
<source><![CDATA[Rev Cuba Reumatol]]></source>
<year>2020</year>
<volume>22</volume>
<numero>3</numero>
<issue>3</issue>
</nlm-citation>
</ref>
<ref id="B12">
<label>12</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Prada]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Gómez]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Lorenzo]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Corrales]]></surname>
<given-names><![CDATA[O]]></given-names>
</name>
<name>
<surname><![CDATA[López]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[González]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Phase I Clinical Trial with a Novel Altered Peptide Ligand Derived from Human Heat-Shock Protein 60 for Treatment of Rheumatoid Arthritis: Safety, Pharmacokinetics and Preliminary Therapeutic Effects]]></article-title>
<source><![CDATA[J Clin Trials]]></source>
<year>2018</year>
<volume>8</volume>
<numero>1</numero>
<issue>1</issue>
</nlm-citation>
</ref>
<ref id="B13">
<label>13</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Venegas-Rodríguez]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Santana-Sanchez]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Peña-Ruiz]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Bequet-Romero]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Hernández-Cedeño]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Santiesteban-Licea]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[CIGB-258, péptido inmumodulador para el tratamiento de pacientes graves y críticos con COVID-19]]></article-title>
<source><![CDATA[Revista Cubana de Medicina Militar]]></source>
<year>2020</year>
<volume>49</volume>
<numero>4</numero>
<issue>4</issue>
</nlm-citation>
</ref>
<ref id="B14">
<label>14</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Hernandez-Cedeño]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Venegas-Rodriguez]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Peña-Ruiz]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Bequet-Romero]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Santana-Sanchez]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Penton-Arias]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[CIGB-258, a peptide derived from human heat-shock protein 60, decreases hyperinflammation in COVID-19 patients]]></article-title>
<source><![CDATA[Cell Stress and Chaperones]]></source>
<year>2021</year>
<volume>26</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>515-25</page-range></nlm-citation>
</ref>
<ref id="B15">
<label>15</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Baldomero Hernández]]></surname>
<given-names><![CDATA[JE]]></given-names>
</name>
<name>
<surname><![CDATA[Del Río Martín]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[del Rosario Cruz]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Venegas Rodríguez]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Hernández Cedeño]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Serrano Diaz]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Early Treatment with a Peptide Derived from the Human Heat-Shock 60 Protein Avoids Progression to Severe Stages of COVID-19]]></article-title>
<source><![CDATA[J Biotechnol Biomed]]></source>
<year>2021</year>
<volume>4</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>196-210</page-range></nlm-citation>
</ref>
<ref id="B16">
<label>16</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Venegas Rodríguez]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Serrano Díaz]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Peña Ruiz]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Santana Sánchez]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Rittoles Navarro]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Grecesqui Cruz]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Jusvinza. An anti-inflammatory drug derived from the human heat-shock protein 60, for critically ill COVID-19 patients. An observational study]]></article-title>
<source><![CDATA[PLoSONE]]></source>
<year></year>
<volume>18</volume>
<numero>2</numero>
<issue>2</issue>
</nlm-citation>
</ref>
<ref id="B17">
<label>17</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Domínguez-Horta]]></surname>
<given-names><![CDATA[MC]]></given-names>
</name>
<name>
<surname><![CDATA[Serrano-Díaz]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Hernández-Cedeño]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Martínez-Donato]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Guillén-Nieto]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[A peptide derived from HSP60 reduces proinflammatory cytokines and soluble mediators: a therapeutic approach to inflammation]]></article-title>
<source><![CDATA[Front. Immunol]]></source>
<year>2023</year>
<volume>14</volume>
</nlm-citation>
</ref>
<ref id="B18">
<label>18</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[England]]></surname>
<given-names><![CDATA[BR]]></given-names>
</name>
<name>
<surname><![CDATA[Tiong]]></surname>
<given-names><![CDATA[BK]]></given-names>
</name>
<name>
<surname><![CDATA[Bergman]]></surname>
<given-names><![CDATA[MJ]]></given-names>
</name>
<name>
<surname><![CDATA[Curtis]]></surname>
<given-names><![CDATA[JR]]></given-names>
</name>
<name>
<surname><![CDATA[Kazi]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Mikuls]]></surname>
<given-names><![CDATA[TR]]></given-names>
</name>
<name>
<surname><![CDATA[O'Dell]]></surname>
<given-names><![CDATA[JR]]></given-names>
</name>
<name>
<surname><![CDATA[Ranganath]]></surname>
<given-names><![CDATA[VK]]></given-names>
</name>
<name>
<surname><![CDATA[Limanni]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Suter]]></surname>
<given-names><![CDATA[LG]]></given-names>
</name>
<name>
<surname><![CDATA[Michaud]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[2019 Update of the American College of Rheumatology Recommended Rheumatoid Arthritis Disease Activity Measures]]></article-title>
<source><![CDATA[Arthritis Care Res (Hoboken)]]></source>
<year>2019</year>
<volume>71</volume>
<numero>12</numero>
<issue>12</issue>
<page-range>1540-55</page-range></nlm-citation>
</ref>
<ref id="B19">
<label>19</label><nlm-citation citation-type="book">
<collab>GUIPCAR, Grupo</collab>
<source><![CDATA[Guía de práctica clínica para el manejo de la artritis reumatoide en España]]></source>
<year>2001</year>
<publisher-loc><![CDATA[Sociedad Española de Reumatología, Madrid ]]></publisher-loc>
<publisher-name><![CDATA[Edit. Doyma]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B20">
<label>20</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Reyes Llerena]]></surname>
<given-names><![CDATA[GA]]></given-names>
</name>
<name>
<surname><![CDATA[Penedo]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Guibert Toledano]]></surname>
<given-names><![CDATA[ZM]]></given-names>
</name>
<name>
<surname><![CDATA[Hernández Martínez]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[González]]></surname>
<given-names><![CDATA[IR]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Validación de la versión cubana de la dimensión física del Cuestionario de Evaluación de Salud (HAQ) en cubanos con artritis reumatoide (CUHAQ)]]></article-title>
<source><![CDATA[Revista Cubana de Reumatología]]></source>
<year>2002</year>
<volume>4</volume>
<page-range>43-55</page-range></nlm-citation>
</ref>
<ref id="B21">
<label>21</label><nlm-citation citation-type="journal">
<collab>World Medical Association</collab>
<article-title xml:lang=""><![CDATA[World medical declaration of Helsinki: ethical principles for medical research involving human subjects]]></article-title>
<source><![CDATA[J Am Med Assoc]]></source>
<year>2013</year>
<volume>310</volume>
<page-range>2191-4</page-range></nlm-citation>
</ref>
<ref id="B22">
<label>22</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Toussirot]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Predictive factors for disability as evaluated by the health assessment questionnaire in rheumatoid arthritis: a literature review]]></article-title>
<source><![CDATA[Inflamm Allergy Drug Targets]]></source>
<year>2010</year>
<volume>9</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>51-9</page-range></nlm-citation>
</ref>
<ref id="B23">
<label>23</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Tanaka]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Mannalithara]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Inoue]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Hara]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Tomatsu]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Kamatani]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Singh]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Yamanaka]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Efficient management of rheumatoid arthritis significantly reduces long-term functional disability]]></article-title>
<source><![CDATA[Ann Rheum Dis]]></source>
<year>2008</year>
<volume>67</volume>
<numero>8</numero>
<issue>8</issue>
<page-range>1153-8</page-range></nlm-citation>
</ref>
<ref id="B24">
<label>24</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Batlle-Gualda]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Chalmeta]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Calidad de vida en la artritis reumatoide]]></article-title>
<source><![CDATA[Revista Española de Reumatología]]></source>
<year>2002</year>
<volume>1</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>12-9</page-range></nlm-citation>
</ref>
<ref id="B25">
<label>25</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Corrales]]></surname>
<given-names><![CDATA[O]]></given-names>
</name>
<name>
<surname><![CDATA[Hernández]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Prada]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Gómez]]></surname>
<given-names><![CDATA[JA]]></given-names>
</name>
<name>
<surname><![CDATA[Reyes]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[López]]></surname>
<given-names><![CDATA[AM]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[CIGB-814, an altered peptide ligand derived from human heat-shock protein 60, decreases anti-cyclic citrullinated peptides antibodies in patients with rheumatoid arthritis]]></article-title>
<source><![CDATA[Clinical Rheumatology]]></source>
<year>2019</year>
</nlm-citation>
</ref>
<ref id="B26">
<label>26</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Domínguez Horta]]></surname>
<given-names><![CDATA[MC]]></given-names>
</name>
<name>
<surname><![CDATA[Cabrales]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Lorenzo]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Padrón]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Gonzalez]]></surname>
<given-names><![CDATA[LJ]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Biodistribution and pharmacokinetic profiles of an altered peptide ligand derived from heat-shock proteins 60 in Lewis rats]]></article-title>
<source><![CDATA[Cell Stress and Chaperones]]></source>
<year>2020</year>
<volume>25</volume>
<page-range>133-40</page-range></nlm-citation>
</ref>
<ref id="B27">
<label>27</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Cho]]></surname>
<given-names><![CDATA[KH]]></given-names>
</name>
<name>
<surname><![CDATA[Nam]]></surname>
<given-names><![CDATA[HS]]></given-names>
</name>
<name>
<surname><![CDATA[Kim]]></surname>
<given-names><![CDATA[JE]]></given-names>
</name>
<name>
<surname><![CDATA[Na]]></surname>
<given-names><![CDATA[HJ]]></given-names>
</name>
<name>
<surname><![CDATA[Dominguez-Horta]]></surname>
<given-names><![CDATA[MC]]></given-names>
</name>
<name>
<surname><![CDATA[Martinez-Donato]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[CIGB-258 Exerts Potent Anti-In&#64258;ammatory Activity against Carboxymethyl lysine Induced Acute In&#64258;ammation in Hyperlipidemic Zebra&#64257;sh via the Protection of Apolipoprotein A-I]]></article-title>
<source><![CDATA[Int. J. Mol. Sci]]></source>
<year>2023</year>
<volume>24</volume>
</nlm-citation>
</ref>
</ref-list>
</back>
</article>
